Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
5.07
Dollar change
-0.29
Percentage change
-5.41
%
IndexRUT P/E- EPS (ttm)-1.46 Insider Own23.98% Shs Outstand78.37M Perf Week-7.14%
Market Cap462.08M Forward P/E- EPS next Y-1.06 Insider Trans1.48% Shs Float69.29M Perf Month17.09%
Income-120.74M PEG- EPS next Q-0.23 Inst Own86.05% Short Float10.50% Perf Quarter-16.61%
Sales0.00M P/S- EPS this Y44.85% Inst Trans10.11% Short Ratio2.51 Perf Half Y81.72%
Book/sh2.90 P/B1.75 EPS next Y-8.13% ROA-42.15% Short Interest7.28M Perf Year69.00%
Cash/sh2.91 P/C1.74 EPS next 5Y38.60% ROE-50.60% 52W Range1.57 - 8.40 Perf YTD11.67%
Dividend Est.- P/FCF- EPS past 5Y-29.69% ROI-41.50% 52W High-39.64% Beta1.31
Dividend TTM- Quick Ratio20.62 Sales past 5Y0.00% Gross Margin- 52W Low222.93% ATR (14)0.57
Dividend Ex-Date- Current Ratio20.62 EPS Y/Y TTM40.91% Oper. Margin0.00% RSI (14)46.68 Volatility8.33% 10.54%
Employees71 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price15.67
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q60.82% Payout- Rel Volume0.63 Prev Close5.36
Sales Surprise- EPS Surprise38.18% Sales Q/Q- EarningsMay 13 BMO Avg Volume2.90M Price5.07
SMA20-4.74% SMA50-0.50% SMA20025.01% Trades Volume1,832,364 Change-5.41%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Upgrade JP Morgan Neutral → Overweight $11
Dec-21-23Upgrade BofA Securities Neutral → Buy $4 → $6
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Jun-18-24 08:00AM
Jun-17-24 04:05PM
Jun-07-24 09:40AM
Jun-05-24 11:04PM
10:57AM
09:55AM Loading…
09:55AM
04:45AM
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
04:05PM Loading…
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM Loading…
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
06:30AM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carson William H.DirectorJun 03 '24Buy4.833,20015,4599,600Jun 05 04:23 PM
Carson William H.DirectorMay 01 '24Buy4.683,20014,9826,400May 03 04:15 PM
Carson William H.DirectorApr 08 '24Buy6.073,20019,4113,200Apr 10 07:17 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 20 '24Sale5.512,60414,34872,471Feb 21 04:31 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 20 '24Sale5.532,59314,33982,058Feb 21 04:31 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 20 '24Sale5.481,95110,69185,641Feb 21 04:31 PM
Love DouglasPRESIDENT AND CEOFeb 12 '24Sale5.545,78232,032196,121Feb 14 07:56 PM
Yednock TedEVP & CHIEF INNOVATION OFFICERFeb 12 '24Sale5.541,81010,02736,075Feb 14 07:52 PM
Lew JenniferEVP & CHIEF FINANCIAL OFFICERFeb 12 '24Sale5.541,80910,02245,651Feb 14 07:54 PM
Overdorf MichaelEVP & CHIEF BUSINESS OFFICERFeb 12 '24Sale5.531,3497,46048,592Feb 14 07:59 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Option Exercise1.6321,00034,17621,000Dec 29 04:12 PM
Yednock TedEVP & Chief Innovation OfficerDec 27 '23Sale4.5221,00094,9660Dec 29 04:12 PM
Satter Muneer ADirectorDec 26 '23Buy2.88350,0001,008,0007,406,024Dec 28 04:30 PM
Lew JenniferEVP & Chief Financial OfficerJul 11 '23Sale3.841,0574,05547,460Jan 23 04:57 PM
Overdorf MichaelEVP & Chief Business OfficerJul 11 '23Sale3.849783,75245,802Jan 23 04:58 PM
Last Close
Jun 18 04:00PM ET
0.9469
Dollar change
-0.0031
Percentage change
-0.33
%
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-2.57 Insider Own43.84% Shs Outstand27.61M Perf Week-15.46%
Market Cap34.95M Forward P/E- EPS next Y-0.94 Insider Trans3.06% Shs Float20.73M Perf Month-16.94%
Income-70.96M PEG- EPS next Q-0.23 Inst Own11.10% Short Float2.15% Perf Quarter38.23%
Sales0.00M P/S- EPS this Y49.82% Inst Trans-4.43% Short Ratio0.34 Perf Half Y33.37%
Book/sh0.75 P/B1.27 EPS next Y32.62% ROA-73.11% Short Interest0.45M Perf Year-68.44%
Cash/sh0.92 P/C1.03 EPS next 5Y- ROE-128.37% 52W Range0.49 - 2.98 Perf YTD72.16%
Dividend Est.- P/FCF- EPS past 5Y-44.91% ROI-211.02% 52W High-68.22% Beta-0.06
Dividend TTM- Quick Ratio2.19 Sales past 5Y0.00% Gross Margin- 52W Low93.24% ATR (14)0.10
Dividend Ex-Date- Current Ratio2.19 EPS Y/Y TTM21.31% Oper. Margin0.00% RSI (14)41.08 Volatility6.51% 10.53%
Employees73 Debt/Eq0.35 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq0.31 EPS Q/Q25.34% Payout- Rel Volume0.07 Prev Close0.95
Sales Surprise-100.00% EPS Surprise-463.64% Sales Q/Q- EarningsMay 14 BMO Avg Volume1.31M Price0.95
SMA20-10.09% SMA50-15.90% SMA200-22.94% Trades Volume96,675 Change-0.33%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Jun-13-24 04:05PM
May-29-24 06:05AM
May-14-24 01:54PM
07:30AM
Apr-16-24 09:14AM
10:53PM Loading…
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
04:01PM Loading…
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
07:30AM Loading…
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08 '24Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12 '24Sale0.83560465734,813Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11 '24Sale0.87569495735,373Jan 16 06:16 PM